PRL and myeloid sarcoma: Therefore, we suggest that the blood CD244+CX3CR1+CD45RA−CCR7− CD8+ TEM subset is a cellular correlate of PRL burden, which should be investigated as a tool to measure response to therapeutic interventions for ameliorating progression in MS.